Search research articles
Contact Us
Filters
Showing results (1-10 of 7) with videos related to
Page
of 1
Sort By:
The Hematology Journal : the Official Journal of the European Haematology Association
|
December 13, 2003
Elevated serum angiogenin in multiple myeloma
Michael G Alexandrakis, Freda H Passam, Aikaterini Sfiridaki, et al.
Journal of Hematology & Oncology
|
May 10, 2011
Circulating osteopontin: a dual marker of bone destruction and angiogenesis in patients with multiple myeloma
Aikaterini Sfiridaki, Spiros Miyakis, Constantina Pappa, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry
|
January 20, 2007
Relationship between serum levels of vascular endothelial growth factor, hepatocyte growth factor and matrix metalloproteinase-9 with biochemical markers of bone disease in multiple myeloma
Michael G Alexandrakis, Aikaterini Sfiridaki, Spiros Miyakis, et al.
European Journal of Internal Medicine
|
September 12, 2006
Serum interleukin-17 and its relationship to angiogenic factors in multiple myeloma
Michael G Alexandrakis, Constantina A Pappa, Spiros Miyakis, et al.
Pathology Oncology Research : POR
|
March 5, 2013
The significance of non correlation between interleukin-8 serum levels with bone marrow microvascular density in patients with myeloma multiple
Constantina A Pappa, George Tsirakis, Anna Boula, et al.
Acta Haematologica
|
December 3, 2020
Role of Inherited Thrombophilia Risk Factors in Patients with CKD-5 Receiving Haemodialysis
Dimitra Liapi, Aikaterini Sfiridaki, Aikaterini Livadiotaki, et al.
Clinical Chemistry and Laboratory Medicine
|
September 24, 2005
Systemic levels of interleukin-6 and matrix metalloproteinase-9 in patients with multiple myeloma may be useful as prognostic indexes of bone disease
Aikaterini Sfiridaki, Spiros Miyakis, George Tsirakis, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 7) with videos related to
Sort By:
Page
of 1
The Hematology Journal : the Official Journal of the European Haematology Association
|
December 13, 2003
Elevated serum angiogenin in multiple myeloma
Michael G Alexandrakis, Freda H Passam, Aikaterini Sfiridaki, et al.
Journal of Hematology & Oncology
|
May 10, 2011
Circulating osteopontin: a dual marker of bone destruction and angiogenesis in patients with multiple myeloma
Aikaterini Sfiridaki, Spiros Miyakis, Constantina Pappa, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry
|
January 20, 2007
Relationship between serum levels of vascular endothelial growth factor, hepatocyte growth factor and matrix metalloproteinase-9 with biochemical markers of bone disease in multiple myeloma
Michael G Alexandrakis, Aikaterini Sfiridaki, Spiros Miyakis, et al.
European Journal of Internal Medicine
|
September 12, 2006
Serum interleukin-17 and its relationship to angiogenic factors in multiple myeloma
Michael G Alexandrakis, Constantina A Pappa, Spiros Miyakis, et al.
Pathology Oncology Research : POR
|
March 5, 2013
The significance of non correlation between interleukin-8 serum levels with bone marrow microvascular density in patients with myeloma multiple
Constantina A Pappa, George Tsirakis, Anna Boula, et al.
Acta Haematologica
|
December 3, 2020
Role of Inherited Thrombophilia Risk Factors in Patients with CKD-5 Receiving Haemodialysis
Dimitra Liapi, Aikaterini Sfiridaki, Aikaterini Livadiotaki, et al.
Clinical Chemistry and Laboratory Medicine
|
September 24, 2005
Systemic levels of interleukin-6 and matrix metalloproteinase-9 in patients with multiple myeloma may be useful as prognostic indexes of bone disease
Aikaterini Sfiridaki, Spiros Miyakis, George Tsirakis, et al.
Page
of 1